Highly sensitive immunoassay of free prostate-specific antigen in serum using europium(III) nanoparticle label technology

Clinica Chimica Acta

Volumn 328, Issue 1-2, 2003, Pages 45-58

  Soukka, Tero ^a   Antonen, Katri ^a   Härmä, Harri ^a   Pelkkikangas, Anne Maria ^a   Huhtinen, Petri ^a   Lövgren, Timo ^a  

^a UNIVERSITY OF TURKU   (Finland)

Author keywords

Nanoparticle label technology; Prostate specific antigen; Time resolved fluorometry

Indexed keywords

EUROPIUM; MONOCLONAL ANTIBODY; NANOPARTICLE; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FLUOROMETRY; HUMAN; IMMUNOASSAY; MALE; MICROTITER PLATE ASSAY; PRIORITY JOURNAL; PROSTATE; PROSTATECTOMY;

EUROPIUM; FLUOROMETRY; HUMANS; IMMUNOASSAY; MALE; PROSTATE-SPECIFIC ANTIGEN; SENSITIVITY AND SPECIFICITY;

EID: 0037307403     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(02)00376-5     Document Type: Article

References (38)

1. Stephan C., Jung K., Diamandis E.P., Rittenhouse H.G., Lein M., Loening S.A. Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer. Urology. 59:2002;2-8.
2. Finne P., Zhang W.M., Auvinen A.et al. Use of the complex between prostate specific antigen and alpha 1-protease inhibitor for screening prostate cancer. J. Urol. 164:2000;1956-1960.
3. Zhang W.M., Finne P., Leinonen J., Salo J., Stenman U.H. Determination of prostate-specific antigen complexed to alpha(2)-macroglobulin in serum increases the specificity of free to total PSA for prostate cancer. Urology. 56:2000;267-272.
4. Stenman U.H., Leinonen J., Zhang W.M., Finne P. Prostate-specific antigen. Semin. Cancer Biol. 9:1999;83-93.
5. Nurmikko P., Pettersson K., Piironen T., Hugosson J., Lilja H. Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146. Clin. Chem. 47:2001;1415-1423.
6. Lilja H., Christensson A., Dahlen U.et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin. Chem. 37:1991;1618-1625.
7. Stenman U.H., Leinonen J., Alfthan H., Rannikko S., Tuhkanen K., Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 51:1991;222-226.
8. Diamandis E.P., Yu H., Melegos D.N. Ultrasensitive prostate-specific antigen assays and their clinical application. Clin. Chem. 42:1996;853-857.
9. Ferguson R.A., Yu H., Kalyvas M., Zammit S., Diamandis E.P. Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers. Clin. Chem. 42:1996;675-684.
10. Black M.H., Giai M., Ponzone R., Sismondi P., Yu H., Diamandis E.P. Serum total and free prostate-specific antigen for breast cancer diagnosis in women. Clin. Cancer Res. 6:2000;467-473.
11. Becker C., Piironen T., Pettersson K., Hugosson J., Lilja H. Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater. Urology. 55:2000;694-699.
12. Becker C., Piironen T., Kiviniemi J., Lilja H., Pettersson K. Sensitive and specific immunodetection of human glandular kallikrein 2 in serum. Clin. Chem. 46:2000;198-206.
13. Kricka L.J. Selected strategies for improving sensitivity and reliability of immunoassays. [Review] Clin. Chem. 40:1994;347-357.
14. Hemmilä I., Mukkala V.-M. Time-resolution in fluorometry technologies, labels, and applications in bioanalytical assays. [Review] Crit. Rev. Clin. Lab. Sci. 38:2002;441-519.
15. Dickson E.F., Pollak A., Diamandis E.P. New trends in photobiology: time-resolved detection of lanthanide luminescence for ultrasensitive bioanalytical assays. [Review] J. Photochem. Photobiol., B. 27:1995;3-19.
16. Morton R.C., Diamandis E.P. Streptavidin-based macromolecular complex labeled with a Europium chelator suitable for time-resolved fluorescence immunoassay applications. Anal. Chem. 62:1990;1841-1845.
17. Scorilas A., Bjartell A., Lilja H., Moller C., Diamandis E.P. Streptavidin-polyvinylamine conjugates labeled with a europium chelate: applications in immunoassay, immunohistochemistry, and microarrays. Clin. Chem. 46:2000;1450-1455.
18. Qin Q.P., Lövgren T., Pettersson K. Development of highly fluorescent detection reagents for the construction of ultrasensitive immunoassays. Anal. Chem. 73:2001;1521-1529.
19. Härmä H., Soukka T., Lönnberg S., Paukkunen J., Tarkkinen P., Lövgren T. Zeptomole detection sensitivity of prostate-specific antigen in a rapid microtitre plate assay using time-resolved fluorescence. Luminescence. 15:2000;351-355.
20. Härmä H., Soukka T., Lövgren T. Europium nanoparticles and time-resolved fluorescence for ultrasensitive detection of prostate-specific antigen. Clin. Chem. 47:2001;561-568.
21. Soukka T., Härmä H., Paukkunen J., Lövgren T. Immunoassays based on multivalent nanoparticle-antibody bioconjugates utilize kinetically enhanced monovalent binding affinity. Anal. Chem. 73:2001;2254-2260.
22. Soukka T., Paukkunen J., Härmä H., Lönnberg S., Lindroos H., Lövgren T. Supersensitive time-resolved immunofluorometric assay of free prostate-specific antigen with nanoparticle label technology. Clin. Chem. 47:2001;1269-1278.
23. Lövgren J., Piironen T., Övermo C.et al. Production of recombinant PSA and HK2 and analysis of their immunologic cross-reactivity. Biochem. Biophys. Res. Commun. 213:1995;888-895.
24. Piironen T., Villoutreix B.O., Becker C.et al. Determination and analysis of antigenic epitopes of prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2) using synthetic peptides and computer modelling. Protein Sci. 7:1998;259-269.
25. Xu R. Particle characterization: light scattering methods. 2000;Kluwer Academic Publishing, Dordrecht.
26. Ullman E.F., Kirakossian H., Singh S.et al. Luminescent oxygen channeling immunoassay: measurement of particle binding kinetics by chemiluminescence. Proc. Natl. Acad. Sci. U. S. A. 91:1994;5426-5430.
27. Ullman E.F., Kirakossian H., Switchenko A.C.et al. Luminescent oxygen channeling assay (LOCI™): sensitive, broadly applicable homogeneous immunoassay method. Clin. Chem. 42:1996;1518-1526.
28. Zijlmans H.J.M.A.A., Bonnet J., Burton J.et al. Detection of cell and tissue surface antigens using up-converting phosphors: a new reporter technology. Anal. Biochem. 267:1999;30-36.
29. Park S.-J., Taton A., Mirkin C.A. Array-based electrical detection of DNA with nanoparticle probes. Science. 295:2002;1503-1506.
30. Hemmilä I., Dakubu S., Mukkala V.-M., Siitari H., Lövgren T. Europium as a label in time-resolved immunofluorometric assays. Anal. Biochem. 137:1984;335-343.
31. Evangelista R.A., Pollak A., Templeton E.F. Enzyme-amplified lanthanide luminescence for enzyme detection in bioanalytical assays. Anal. Biochem. 197:1991;213-224.
32. Ekins R.P., Chu F.W. Multianalyte microspot immunoassay - microanalytical "compact disk" of the future. Clin. Chem. 37:1991;1955-1967.
33. Ekins R.P., Dakubu S. The development of high sensitivity pulsed light, time-resolved fluoroimmunoassays. Pure Appl. Chem. 57:1985;437-482.
34. Piironen T., Pettersson K., Suonpaa M.et al. In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin in blood samples. Urology. 48:1996;81-87.
35. Qin Q.P., Christiansen M., Pettersson K. Point-of-care time-resolved immunofluorometric assay for human pregnancy-associated plasma protein A: use in first-trimester screening for Down syndrome. Clin. Chem. 48:2002;473-483.
36. Pettersson K., Katajamäki T., Irjala K., Leppänen V., Majamaa-Voltti K., Laitinen P. Time-resolved fluorometry (TRF)-based immunoassay concept for rapid and quantitative determination of biochemical myocardial infarction markers from whole blood, serum and plasma. Luminescence. 15:2000;399-407.
37. Vassilikos E.J., Yu H., Trachtenberg J.et al. Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up. Clin. Biochem. 33:2000;115-123.
38. Scorilas A., Yu H., Soosaipillai A.R., Gregorakis A.K., Diamandis E.P. Comparison of the percent free prostate-specific antigen levels in the serum of healthy men and in men with recurrent prostate cancer after radical prostatectomy. Clin. Chim. Acta. 292:2000;127-138.